Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:skincare_product
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Daytrana
|
| gptkbp:activities |
CNS stimulant
|
| gptkbp:application |
hip
|
| gptkbp:body_style |
rectangular
|
| gptkbp:brand |
gptkb:Daytrana
|
| gptkbp:class |
stimulants
|
| gptkbp:clinical_trial |
Phase III
ADHD management |
| gptkbp:color |
beige
|
| gptkbp:contraindication |
gptkb:sneaker
heart problems hyperthyroidism history of substance abuse |
| gptkbp:dosage_form |
gptkb:spacecraft
|
| gptkbp:duration |
up to 9 hours
after 9 hours |
| gptkbp:education |
apply to clean, dry skin
dispose of properly after use do not cut the patch |
| gptkbp:effective_date |
2006-04-06
|
| gptkbp:formulation |
matrix patch
|
| https://www.w3.org/2000/01/rdf-schema#label |
Daytrana Patch
|
| gptkbp:ingredients |
gptkb:drug
|
| gptkbp:interacts_with |
antidepressants
MAO inhibitors antihypertensives |
| gptkbp:is_used_for |
treatment of ADHD
|
| gptkbp:manager |
transdermal
|
| gptkbp:manufacturer |
Noven Pharmaceuticals
|
| gptkbp:marketed_as |
gptkb:Australia
gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:packaging |
single-use pouch
|
| gptkbp:pharmacokinetics |
absorbed through skin
increases dopamine and norepinephrine |
| gptkbp:population |
children and adolescents
|
| gptkbp:premiered_on |
approximately 2 hours
|
| gptkbp:regulatory_compliance |
FDA approved
|
| gptkbp:release_format |
extended-release
|
| gptkbp:requires |
prescription only
|
| gptkbp:side_effect |
anxiety
dizziness headache nausea decreased appetite insomnia dry mouth tics irritation at application site |
| gptkbp:size |
10 cm²
|
| gptkbp:storage |
room temperature
|
| gptkbp:type_of_care |
improved adherence due to ease of use
|